Investment Thesis:
- Global leader in invasive and non-invasive inhalation, nasal high flow therapy and during surgery.
- Strong global market position in a significantly under-penetrated treatment of sleep apnea market and chronic obstructive pulmonary disease.
- Increasing uptake of Nasal high-flow (NHF) therapy and consumables growth on the back of this.
- High barriers to entry in establishing global distribution channels.
- Strong R&D program ensuring FPH remains ahead of competitors.
- New product releases
- Bolt-on acquisitions to supplement organic growth.
Key Risks:
- Consolidation / normalization of sales post the COVID-19 driven demand.
- Disruptive technology leading to better patient compliance.
- Product recall leading to reputational damage.
- Competitive threats leading to market share loss.
- Disappointing growth (company and industry specific).
- Adverse currency movements.
- FPH needs to grow to maintain its high PE trading multiple. Therefore, any impact on growth may put pressure on FPH’s valuation.
Key highlights:
- Fisher & Paykel Healthcare Corp (FPH) reported very strong FY21 results, with operating revenue of $1.97bn up+56% (or +61% in constant currency (CC)) and earnings (NPAT) of $524m up +82% (or+94% in CC) over the previous corresponding period (pcp).
- FPH saw an increase of +49% (constant currency) in revenue for new applications consumables; i.e. products used in non-invasive ventilation, Optiflow nasal high flow therapy and surgical applications, accounting for 66% of Hospital consumables revenue.
- The Board declared a final dividend to 22.0cps up +42% on pcp. Total dividend for FY21 of 38.0cps was up +38%.
- Balance sheet remains strong with FY21 net cash of $303m, up from $42m in FY20.
- COVID-19 has aggressively accelerated FPH’s global devices installed base and changing clinical practices. FPH achieved +337% growth in hospital hardware in FY21 vs pcp.
Company Description:
Fisher & Paykel Healthcare (FPH) is a designer, manufacturer and marketer of products for use in respiratory care, acute care, surgery and treatment of obstructive sleep apnea. The Company sells its products in over 120 countries. FPH’s products are used in the treatment of more than 12 million patients. In the hospital setting, FPH products are used in invasive inhalation, non-invasive inhalation, nasal high flow therapy, and during surgery. In long-term care facilities and home settings, FPH technologies assist in the treatment of obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions.
(Source: Banyantree)
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.